OCE Oncology News
A monthly newsletter for oncology/hematology fellows, junior faculty and scientists
Related Articles
FDA Finalizes Updated “Healthy” Nutrient Content Claim
FDA has issued a final rule to update the “healthy” nutrient content claim to help consumers identify foods that are particularly useful as the foundation…
Endo USA, Inc. Issues Voluntary, Nationwide Recall of Adrenalin® Chloride Solution (EPINEPHrine Nasal Solution, USP) Due to the Potential for Administration Errors
Endo, Inc (OTCQX: NDOI) (“Endo”), announced today that one of its operating subsidiaries, Endo USA, Inc., is voluntarily recalling all lots within expiry of Adrenalin®…
FDA Approves First Medication for Obstructive Sleep Apnea
Today, the FDA approved the first medication for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.
FDA Approves First Medication for Obstructive Sleep Apnea
Today, the FDA approved the first medication for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.
OCE PULSE: January FDA Oncology Events, Recent Approvals and Publications
Click to share this newsletter with your colleagues! OCE PULSE offers a summary of FDA Oncology Center of Excellence (OCE) upcoming public events, educational opportunities,…
FDA Approves First Medication for Obstructive Sleep Apnea
Today, the FDA approved the first medication for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.
FDA grants accelerated approval
The Food and Drug Administration granted accelerated approval to encorafenib.
FDA Approves First Medication for Obstructive Sleep Apnea
Today, the FDA approved the first medication for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.
FDA grants accelerated approval
The Food and Drug Administration granted accelerated approval to encorafenib.
OCE Conversations on Cancer – Cervical Cancer Treatment Innovation: A Collaborative Discussion
Take this survey powered by surveymonkey.com. Create your own surveys for free.